ISSN: 0923-7534

Annals of Oncology Q1 Unclaimed

Elsevier Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 242. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has an SJR impact factor of 7,954 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 7,954.

Annals of Oncology focuses its scope in these topics and keywords: cancer, patients, advanced, phase, lung, metastatic, clinical, treatment, trial, ii, ...

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Hematology (Q1) Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

7,954

SJR Impact factor

242

H Index

268

Total Docs (Last Year)

1338

Total Docs (3 years)

8070

Total Refs

14406

Total Cites (3 years)

882

Citable Docs (3 years)

11,13

Cites/Doc (2 years)

30,11

Ref/Doc

Other journals with similar parameters

Nature Reviews Drug Discovery Q1
Annual Review of Pathology: Mechanisms of Disease Q1
NCHS data brief Q1
Molecular Systems Biology Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Screening for carcinomain situ in the contralateral testicle in patients with testicular cancer: a population-based study

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease

Coming into focus: the nonovarian origins of ovarian cancer

Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project

Psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin

A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267

The ESMO Precision Medicine Glossary

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients - the Polish Lymphoma Research Group (PLRG) Observational Study

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94)

Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group

SHOW MORE ARTICLES

Outcome in colorectal cancer - tumour, stroma and so much more

ESMO-MCBS v1.1: statistical and patient-relevant shortcomings

Early ultrasonographic finding of septic thrombophlebitis is the main indicator of central venous catheter removal to reduce infection-related mortality in neutropenic patients with bloodstream infection

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy

Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .